Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...
Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...
Q3 2025 Earnings Call Transcript January 30, 2025 Christopher O’Reilly: [Foreign Language] Let me start, I’d like to remind ...
Takeda Pharmaceuticals has named Julie Kim as the first woman to lead the 244-year-old Japanese drugmaker, a rarity in senior ...
Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co (TKPHF – Research Report).
After leading Japan’s largest drugmaker for 11 years, Takeda CEO Christophe Weber plans to step down in June of 2026. He will ...
US President Donald Trump has warned BRICS nations against introducing a new currency or backing an alternative to the U.S.
Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...
A Lim Kim made enough birdies in an up-and-down second round to maintain a cushion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback